Stockreport

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc.  (IBRX) 
PDF Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially supp [Read more]